A Phase 4 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 48 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-03-27.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 5 that started in 2015, is one of 50 in phase 4, and was the 35th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 53rd largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2015, is one of 9 in phase 4, and was the 96th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin · Drug: Placebo
Drug: Empagliflozin · Drug: Placebo
Drug: Placebo
For blinding purposes
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment.
The primary endpoint was the change from baseline in HbA1c after 16 weeks of treatment. The term "baseline" refers to the last observation prior to the administration of any randomised study drug. Means presented are the adjusted means.
Time frame: Baseline and 16 weeks
Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs)
Percentage of patients with investigator defined drug-related Adverse Events (AEs) are presented
Time frame: From 1st intake of study drug to last intake of study drug + 7 days; up to 53 weeks
After screening, patients who were pre-treated with insulin and 1 oral antidiabetic drug (OAD) underwent a 10-week wash-out period. Then patients proceeded to a 2-week open-label placebo run-in period. Patients who were pre-treated with insulin alone skipped the wash-out period and proceeded to an open-label placebo run-in period.
| Milestone | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Started | 90 | 89 | 90 |
| Treated | 90 | 86 | 90 |
| Completed | 80 | 79 | 86 |
| Not completed | 10 | 10 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Patient withdrawal, not due to ae | 3 | 0 | 0 |
| Withdrew: Adverse event | 4 | 5 | 3 |
| Withdrew: Other reason than specified above | 1 | 2 | 1 |
| Withdrew: Not treated | 0 | 3 | 0 |
The primary endpoint was the change from baseline in HbA1c after 16 weeks of treatment. The term "baseline" refers to the last observation prior to the administration of any randomised study drug. Means presented are the adjusted means.
| percentage of HbA1c | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment. | 0.00 ± 0.07 | -0.92 ± 0.07 | -1.00 ± 0.07 |
Percentage of patients with investigator defined drug-related Adverse Events (AEs) are presented
| Percentage of participants | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Percentage of Patients With Investigator Defined Drug-Related Adverse Events (AEs) | 25.6 | 43.0 | 43.3 |
Collected over From 1st intake of study drug to last intake of study drug + 7 days; up to 53 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/90 (0%) | 6/90 (6.7%) | 49/90 (54.4%) |
| Empagliflozin 10 mg | 1/86 (1.2%) | 9/86 (10.5%) | 45/86 (52.3%) |
| Empagliflozin 25 mg | 0/90 (0%) | 8/90 (8.9%) | 48/90 (53.3%) |
| Event | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| GlaucomaEye disorders | 0/90 | 0/86 | 2/90 |
| Arthritis bacterialInfections and infestations | 0/90 | 1/86 | 0/90 |
| Chronic sinusitisInfections and infestations | 0/90 | 1/86 | 0/90 |
| Pyelonephritis acuteInfections and infestations | 0/90 | 1/86 | 0/90 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/90 | 1/86 | 0/90 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/90 | 1/86 | 0/90 |
| DeliriumPsychiatric disorders | 0/90 | 1/86 | 0/90 |
| Vocal cord paralysisNervous system disorders | 0/90 | 1/86 | 0/90 |
| Coronary artery stenosisCardiac disorders | 0/90 | 1/86 | 0/90 |
| Myocardial infarctionCardiac disorders | 0/90 | 1/86 | 0/90 |
| Event | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 28/90 | 30/86 | 24/90 |
| HypoglycaemiaMetabolism and nutrition disorders | 19/90 | 24/86 | 25/90 |
| PollakiuriaRenal and urinary disorders | 2/90 | 9/86 | 9/90 |
| Asymptomatic bacteriuriaInfections and infestations | 8/90 | 3/86 | 5/90 |
| Back painMusculoskeletal and connective tissue disorders | 3/90 | 5/86 | 6/90 |
| EczemaSkin and subcutaneous tissue disorders | 5/90 | 5/86 | 2/90 |
| Blood ketone body increasedInvestigations | 1/90 | 5/86 | 2/90 |
The full analysis set (FAS) consisted of all patients in the treated set (TS) who had a baseline measurement of the primary endpoint. (The treated set (TS) consisted of all randomised patients who were treated with at least 1 dose of the study drug during the 52-week double blind treatment period. The TS was the basis for safety analyses)
| Age, Continuous(years) | Empagliflozin 10 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.1 ± 10.7 | 58.3 ± 10.0 | 58.6 ± 9.5 | 58.7 ± 10.0 |
| Sex: Female, Male(Participants) | Empagliflozin 10 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 21 | 23 | 29 | 73 |
| Male | 69 | 63 | 61 | 193 |
| Race and Ethnicity Not Collected(Participants) | Empagliflozin 10 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Baseline glycosylated haemoglobin A1c (HbA1c) [%](% of HbA1c) | Empagliflozin 10 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.70 ± 0.68 | 8.83 ± 0.66 | 8.74 ± 0.72 | 8.75 ± 0.69 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Apr 2017, 17 months.
Results were first posted in Mar 2019, 1 year 11 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 17 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin